ByteDance has completed a $290 million fundraising round for its artificial intelligence drug discovery business following the unit’s separation from the Chinese technology group, according to people familiar with the matter. The transaction gives the newly independent company, Anew Labs, a valuation of approximately $1.5 billion and marks a significant step in its effort to develop AI-driven approaches to pharmaceutical research.
Shanghai-based Anew Labs focuses on using artificial intelligence to support drug discovery, an area that has attracted increasing attention from technology companies, biotechnology firms and investors. The completion of the funding round provides the company with substantial new capital as it builds its operations independently of ByteDance and seeks to develop its position in the rapidly evolving AI-enabled healthcare sector.
The fundraising represents Anew Labs’ first external investment round since being spun off from ByteDance. The $290 million financing was led by HSG, previously known as Sequoia China, along with IDG Capital and Hillhouse Investment. 5Y Capital also participated as a co-lead investor, highlighting the level of interest among major technology and investment firms in the potential of artificial intelligence to reshape pharmaceutical research.
Several other investors joined the financing. They included Gaorong Ventures, Primavera Venture Partners and Boyu Capital, along with strategic investor SBP Group and the state-backed Shanghai Future Industries Fund. The participation of both private investment firms and strategic and state-backed investors reflects the broader interest surrounding AI applications in healthcare and life sciences.
Anew Labs’ reported $1.5 billion valuation gives the company a substantial starting point as an independent business. The valuation also places the venture among a growing group of companies attempting to combine advanced computing with biotechnology. While AI drug discovery remains a developing field, companies operating in the space are seeking ways to reduce the time and cost involved in identifying potential drug candidates and understanding how they may interact with biological targets.
The decision to separate Anew Labs from ByteDance appears to reflect the different requirements of the pharmaceutical industry compared with the social media and internet businesses that form the core of ByteDance’s operations. One person familiar with the matter said the spin-off was intended to provide greater support for the unit’s long-term development because AI-based drug discovery follows a different industry logic and requires a different management approach.
That distinction is important because pharmaceutical research generally involves lengthy development timelines, scientific validation and regulatory processes that are very different from the rapid product cycles associated with consumer internet platforms. Drug candidates can take years to move from early research to clinical development, and promising discoveries must undergo extensive testing before they can become approved treatments. For an AI drug discovery company, technological capability is therefore only one part of the equation.
Artificial intelligence can assist researchers by processing large biological and chemical datasets, identifying patterns and suggesting possible drug candidates. In principle, these tools can help researchers explore a much larger number of possibilities than traditional methods alone. However, predictions generated by software still need to be tested through laboratory research and, eventually, clinical trials. The ability to generate promising candidates does not automatically translate into successful medicines.
The separation from ByteDance may allow Anew Labs to develop its business around these specialized requirements while still benefiting from the broader technological expertise associated with its former parent. The move also gives outside investors a direct stake in the AI drug discovery business rather than investing through ByteDance’s wider corporate structure.
Despite the spin-off, ByteDance will continue to hold a majority interest in Anew Labs. Following the fundraising, ByteDance is expected to retain a 56% stake in the company. This means the technology group remains the controlling shareholder while allowing external investors to provide capital and participate in the future development of the business.
For ByteDance, maintaining majority ownership could provide a way to preserve its exposure to the potential long-term value of AI applications in life sciences while giving Anew Labs greater independence. The structure also allows the new company to raise external funding without fully separating itself from the resources and backing of its former parent.
The fundraising comes at a time when artificial intelligence is expanding beyond applications such as search, advertising, entertainment and productivity software. Healthcare and drug development have emerged as important areas for AI research because of the enormous amounts of scientific data involved in understanding diseases, proteins, molecules and potential treatments.
However, the commercial potential of AI drug discovery remains closely tied to scientific results. A high valuation and large fundraising round can provide the resources needed to pursue ambitious research, but they do not guarantee that a company will successfully develop a marketable medicine. The pharmaceutical industry carries considerable scientific, financial and regulatory risks, and many experimental drug candidates ultimately fail during development.
